14) Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets.
Heiny AT, Miotto O, Srinivasan KN, Khan AM, Zhang GL, Brusic V, Tan TW, August JT.
PLoS ONE. 2007 Nov 21;2(11):e1190.
PUBMED PMID: 18030326
Out link: Full-text
Impact Factor Year 2009: 4.351
No. of Citations: 33 (total): 28 (non-self) & 5 (self)
ABSTRACT :
BACKGROUND: Influenza A viruses generate an extreme genetic diversity through point mutation and gene segment exchange, resulting in many new strains that emerge from the animal reservoirs, among which was the recent highly pathogenic H5N1 virus. This genetic diversity also endows these viruses with a dynamic adaptability to their habitats, one result being the rapid selection of genomic variants that resist the immune responses of infected hosts. With the possibility of an influenza A pandemic, a critical need is a vaccine that will recognize and protect against any influenza A pathogen. One feasible approach is a vaccine containing conserved immunogenic protein sequences that represent the genotypic diversity of all current and future avian and human influenza viruses as an alternative to current vaccines that address only the known circulating virus strains.
METHODOLOGY/PRINCIPAL FINDINGS: Methodologies for large-scale analysis of the evolutionary variability of the influenza A virus proteins recorded in public databases were developed and used to elucidate the amino acid sequence diversity and conservation of 36,343 sequences of the 11 viral proteins of the recorded virus isolates of the past 30 years. Technologies were also applied to identify the conserved amino acid sequences from isolates of the past decade, and to evaluate the predicted human lymphocyte antigen (HLA) supertype-restricted class I and II T-cell epitopes of the conserved sequences. Fifty-five (55) sequences of 9 or more amino acids of the polymerases (PB2, PB1, and PA), nucleoprotein (NP), and matrix 1 (M1) proteins were completely conserved in at least 80%, many in 95 to 100%, of the avian and human influenza A virus isolates despite the marked evolutionary variability of the viruses. Almost all (50) of these conserved sequences contained putative supertype HLA class I or class II epitopes as predicted by 4 peptide-HLA binding algorithms. Additionally, data of the Immune Epitope Database (IEDB) include 29 experimentally identified HLA class I and II T-cell epitopes present in 14 of the conserved sequences.
CONCLUSIONS/SIGNIFICANCE: This study of all reported influenza A virus protein sequences, avian and human, has identified 55 highly conserved sequences, most of which are predicted to have immune relevance as T-cell epitopes. This is a necessary first step in the design and analysis of a polyepitope, pan-influenza A vaccine. In addition to the application described herein, these technologies can be applied to other pathogens and to other therapeutic modalities designed to attack DNA, RNA, or protein sequences critical to pathogen function.
This article has been cited by other articles/sites
1. Tripp RA, Tompkins SM Recombinant vaccines for influenza virus. Curr Opin Investig Drugs. (2008). 9 (8), 836-45. PMID: 18666031
2. Lin HH, Zhang GL, Tongchusak S, Reinherz EL, Brusic V. Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinformatics. 2008 Dec 12;9 Suppl 12:S22. PMID: 19091022
3. Khan AM, Miotto O, Nascimento EJ, Srinivasan KN, Heiny AT, Zhang GL, Marques ET, Tan TW, Brusic V, Salmon J, August JT. Conservation and variability of dengue virus proteins: implications for vaccine design. PLoS Negl Trop Dis. 2008 Aug 13;2(8):e272. PMID: 18698358
4. H Rashid, E Haworth, J Ellis, R Booy, S Shafi. Reverse Transcriptase-Polymerase Chain Reaction on QuickVue Influenza Test Strips: A Pilot Study. The Journal of Near-Patient Testing & Technology. 8(1):1-3, March 2009
5. Pappalardo F, Halling-Brown MD, Rapin N, Zhang P, Alemani D, Emerson A, Paci P, Duroux P, Pennisi M, Palladini A, Miotto O, Churchill D, Rossi E, Shepherd AJ, Moss DS, Castiglione F, Bernaschi M, Lefranc MP, Brunak S, Motta S, Lollini PL, Basford KE, Brusic V. ImmunoGrid, an integrative environment for large-scale simulation of the immune system for vaccine discovery, design and optimization. Brief Bioinform. 2009 May;10(3):330-40. PMID: 19383844
6. Chon H, Choi B, Jeong G, Mo I. Evaluation system for an experimental study of low-pathogenic avian influenza virus (H9N2) infection in specific pathogen free chickens using lactic acid bacteria, Lactobacillus plantarum KFCC11389P. Avian Pathol. 2008 Dec;37(6):593-7.PMID: 18923971
7. Tong JC, Ren EC. Immunoinformatics: Current trends and future directions. Drug Discov Today. 2009 Apr 18. [Epub ahead of print]. PMID: 19379830
8. Hemerka JN, Wang D, Weng Y, Lu W, Kaushik RS, Jin J, Harmon AF, Li F.
Detection and characterization of influenza A virus PA-PB2 interaction through a bimolecular fluorescence complementation assay. J Virol. 2009 Apr;83(8):3944-55. Epub 2009 Feb 4.
PMID: 19193801
9. Koo QY, Khan AM, Jung KO, Ramdas S, Miotto O, Tan TW, Brusic V, Salmon J, August JT. Conservation and variability of West Nile virus proteins. PLoS One. 2009;4(4):e5352. Epub 2009 Apr 29. PMID: 19401763
10. http://www.cqvip.com/qk/94860x/2008010/28567073.html
11. Wahl A, Schafer F, Bardet W, Buchli R, Air GM, Hildebrand WH.
HLA class I molecules consistently present internal influenza epitopes.
Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):540-5. Epub 2009 Jan 2.
PMID: 19122146
12. Thompson, W.A., Fan, S., Weltman, J.K. Information entropy of influenza a segment 7 . Entropy. 2008, 10 (4), pp. 736-744
13. Pu, Z., Yu-Shu, Z., Chuan-Ling, Q., Bei-Bei, J.I.A., Xing-You, L.I.U. Strategies exploited by influenza a virus for evading immune responses. Progress in Biochemistry and Biophysics. 2008. 35 (10), pp. 1137-1141
Posts
Subscribe To Posts Via Email
No comments:
Post a Comment